Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lumbricus rubellus extract - Dexa Medica

Next Previous
Drug Profile

Lumbricus rubellus extract - Dexa Medica

Alternative Names: Disolf; DLBS-1033; Lumbricus low molecular weight proteins; Red earthworm extract

Latest Information Update: 18 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dexa Medica
  • Class Alternative medicine; Enzymes; Thrombolytics; Traditional Chinese medicine
  • Mechanism of Action Fibrin inhibitors; Fibrinogen inhibitors; Fibrinolysis stimulants; Fibrinolytic agents; Janus kinase 1 inhibitors; Matrix metalloproteinase 9 inhibitors; NF-kappa B inhibitors; Platelet aggregation inhibitors; STAT1 transcription factor inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Stroke
  • Phase II/III Acute coronary syndromes; Peripheral arterial disorders

Most Recent Events

  • 12 Dec 2023 Dexa Medica terminates a phase II/III ADDLIST trial in Stroke in Indonesia (PO) (NCT02133521)
  • 29 Sep 2020 Phase II/III is ongoing for Stroke (Adjunctive treatment) in Indonesia (NCT04425590)
  • 01 Apr 2020 Dexa Laboratories Of Biomolecular Science initiates enrolment in a phase II/III trial in Stroke (Adjunctive treatment) in Indonesia (PO) (NCT04425590)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top